Empagliflozin (EMP), which is a sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been documented to exhibit inhibitory properties towards various types of cancer cells, including lung cancer, breast cancer, cervical cancer, and hepatocellular carcinoma (HCC) [12]. Here, SLC5A2 is linked to breast carcinoma.